ari-3037mo
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2014 (NCT02250105)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- HM74 nicotinic acid GPCRAGONIST
HCAR3 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ari-3037mo
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02574325 | Phase 2 | Oct 1, 2015 | Arisaph Pharmaceuticals Inc |
| NCT02532218 | Phase 2 | Aug 1, 2015 | Arisaph Pharmaceuticals Inc |
| NCT02250105 | Phase 2 | Sep 1, 2014 | Arisaph Pharmaceuticals Inc, Harvard University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arisaph Pharmaceuticals Inc | For profit | 3 | 3 | 1 | 2014 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2014 |
2 organizations
Page 1 / 1